Influence of β-catenin small interfering RNA on human osteosarcoma cells

Abstract

This study examined the effect of small interfering RNA-mediated β-catenin knockdown on the survival, invasion and chemosensitivity of human osteosarcoma cells (U2-OS cells). The siRNA against β-catenin was constructed and transfected into U2-OS cells. The expression of β-catenin was detected by qRT-PCR and Western blotting. Cell growth and apoptosis was detected in the presence or absence of doxorubicin by MTT and flow cytometry, respectively. Cell invasion ability was measured by transwell assay. The results showed that the transfection of β-catenin siRNA resulted in decreased expression of β-catenin, suppression of invasion and motility of U2-OS cells, reduced chemosensitivity to doxorubicin in vitro, and little change in cell growth and apoptosis. Additionally, down-regulated MT1-MMP expression was found after transfection. It was concluded that knockdown of β-catenin gene may decrease the invasive ability of human osteosarcoma cells through down-regulated MT1-MMP expression, and the chemosensitivity of osteosarcoma cells against doxorubicin.

Keywords

β-catenin / osteosarcoma / siRNA / gene therapy

References

[1] BroadheadM.L., ClarkJ.C., ChoongP.F., et al.. Making gene therapy for osteosarcoma a reality. Expert Rev Anticancer Ther, 2010, 10(4): 477-480

[2] PeiferM., PolakisP.. Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science, 2000, 287(5458): 1606-1609

[3] HoangB.H., KuboT., HealeyJ.H., et al.. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cance, 2004, 109(1): 106-111

[4] GuoY., RubinE.M., XieJ., et al.. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res, 2008, 466(9): 2039-2045

[5] GuoY., ZiX., KoontzZ., et al.. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res, 2007, 25(7): 964-971

[6] HaydonR.C., DeyrupA., IshikawaA., et al.. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer, 2002, 102(4): 338-342

[7] YangF., ZengQ., YuG., et al.. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal, 2006, 18(5): 679-687

[8] IwayaK., OgawaH., KurodaM., et al.. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis, 2003, 20(9): 525-529

[9] IwoaK., MiyoshiY., NawaG., et al.. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res, 1999, 90(2): 205-209

[10] CaiY., MohsenyA.B., KarperienM., et al.. Inactive Wnt/β-catenin pathway in conventional high-grade osteosarcoma. J Pathol, 2010, 220(1): 24-33

[11] ReynoldsA., LeakeD., BoeseQ., et al.. Rational siRNA design for RNA interference. Nat Biotechnol, 2004, 22(3): 326-330

[12] HajraK.M., FearonE.R.. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer, 2002, 34(3): 255-268

[13] PolakisP.. Wnt signaling and cancer. Genes Dev, 2000, 14(15): 1837-1851

[14] VermaU.N., SurabhiR.M., SchmaltiegA., et al.. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res, 2003, 9(4): 1291-300

[15] ZengG., ApteU., CieplyB., et al.. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia, 2007, 9(11): 951-959

[16] PuP., ZhangZ., KangC., et al.. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther, 2009, 16(4): 351-361

[17] KlausA., BirchmeierW.. Wnt signalling and its impact on development and cancer. Nature Rev Cancer, 2008, 8(5): 387-398

[18] ChenK., FallenS., AbaanH.O., et al.. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer, 2008, 51(3): 349-355

[19] HoangB.H., KuboT., HealeyJ.H., et al.. Dickkopf 3 inhibits invasion and motility of saos-2 osteosarcoma cells by modulating the wnt-beta-catenin pathway. Cancer Res, 2004, 64(8): 2734-2739

[20] SeikiM.. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett, 2003, 194(1): 1-11

[21] ZuckerS., PeiD., CaoJ., et al.. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol, 2003, 54: 1-74

[22] DainoK., UgolinN., Altmeyer-MorelS., et al.. Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiationinduced tumorigenesis of bone. Int J Cancer, 2009, 125(3): 612-620

[23] LeowP.C., TianQ., OngZ.Y., et al.. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs, 2010, 28(6): 766-782

[24] KansaraM., TsangM., KodjabachianL., et al.. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest, 2009, 119(4): 837-851

[25] ThomasD.M.. Wnts, bone and cancer. J Pathol, 2010, 220(1): 1-4